Chia-Wei Liu - Concepedia

Author

Chia-Wei Liu

Development Center for Biotechnology ORCID

Also Known As

CHIA-WEI LIU, Chia-Wei Liu, Chia-wei Liu, Chiawei Liu

Publications

296

Citations

H-Index

Concepts

All Affiliations

Development Center for Biotechnology National Chiayi University

About

Chia-Wei Liu is an author at Development Center for Biotechnology specializing in medicine, pharmacology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	161
2	Cell Biology	3	3	77
3	Natural Sciences	2	2	77
4	Biochemistry	2	2	77
5	Chemical Biology	2	2	77

Chia-Wei Liu

Publications

254

Citations

H-Index

Page 1

	Year	Citations
Discovery of Pyrrole−Indoline-2-ones as Aurora Kinase Inhibitors with a Different Inhibition Profile Chao‐Cheng Chiang, Yu‐Hsiang Lin, Shu Lin, Journal of Medicinal Chemistry Medicinal ChemistryPharmaceutical ChemistryBioorganic ChemistryBiochemistryNatural Sciences	2010	59
Discovery of 4-Aryl-<i>N</i>-arylcarbonyl-2-aminothiazoles as Hec1/Nek2 Inhibitors. Part I: Optimization of in Vitro Potencies and Pharmacokinetic Properties Ying-Shuan E. Lee, Shih‐Hsien Chuang, Lynn Y.L. Huang, Journal of Medicinal Chemistry	2014	39
Oxidative stress intensity-related effects of cadmium (Cd) and paraquat (PQ) on UV-damaged-DNA binding and excision repair activities in zebrafish (Danio rerio) embryos Li-Bin Ling, Yung Chang, Chia-Wei Liu, Chemosphere Developmental BiologyBioactive MetalToxicologyDanio RerioUv-damaged-dna Binding	2016	38
Characterization of the biological activity of a potent small molecule Hec1 inhibitor TAI-1 Lynn Y.L. Huang, Ying-Shuan Lee, Jiann‐Jyh Huang, Journal of Experimental & Clinical Cancer Research	2014	36
Inhibition of Hec1 as a novel approach for treatment of primary liver cancer Lynn Y.L. Huang, Chia‐Chi Chang, Ying-Shuan Lee, Cancer Chemotherapy and Pharmacology Primary Liver CancerOncologyHepatologyMedicineHepatobiliary Tumor	2014	25
Discovery of T-1101 tosylate as a first-in-class clinical candidate for Hec1/Nek2 inhibition in cancer therapy Shih‐Hsien Chuang, Ying-Shuan E. Lee, Lynn Y.L. Huang, European Journal of Medicinal Chemistry First-in-class Clinical CandidateT-1101 TosylateHec1/nek2 InhibitionMedicineOncogenic Agent	2020	20
Activity of a Novel Hec1-Targeted Anticancer Compound against Breast Cancer Cell Lines <i>In Vitro</i> and <i>In Vivo</i> Lynn Y.L. Huang, Chia‐Chi Chang, Ying-Shuan Lee, Molecular Cancer Therapeutics Breast OncologyNanotherapeuticsMdr GeneChemoprevention StrategyDrug Targeting	2014	19
Synthesis and structure–activity relationship of 3-O-acylated (–)-epigallocatechins as 5α-reductase inhibitors Shu Lin, Yu‐Hsiang Lin, Mengju Lin, European Journal of Medicinal Chemistry Medicinal Chemistry5α-Reductase InhibitorsBiochemistryNatural SciencesChemical Biology	2010	18

Page 1